MSB 8.25% $1.05 mesoblast limited

Cell Therapy News/Articles, page-158

  1. 5,481 Posts.
    lightbulb Created with Sketch. 8927
    The author of that SA article sounded like an amateur, but that isn’t a surprise with SA.

    My best guess would be that the US institutional investors get tapped next. They set up that avenue last year.

    I also beleive this because SI has indicated that he doesn’t want to partner the paediatric aGVHD program- which is what the phase 3 trial was for.

    Instead he wants to partner the adult aGVHD, class 2/3 CHF (not class 4), RA and chronic lower back pain programs.

    There does appear to be a strong shift in sentiment after the phase 3 success though, so you could be right- that may be the catalyst to CHF or chronic lower back pain getting over the line.

    So I would be very happy to be proven wrong
    Last edited by stockrock: 28/02/18
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.05
Change
0.080(8.25%)
Mkt cap ! $1.198B
Open High Low Value Volume
99.5¢ $1.06 99.0¢ $4.930M 4.779M

Buyers (Bids)

No. Vol. Price($)
1 23545 $1.05
 

Sellers (Offers)

Price($) Vol. No.
$1.05 339479 5
View Market Depth
Last trade - 16.10pm 04/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.